29 results about "Myonectin" patented technology

Provided herein are antibodies or antigen-binding fragments thereof targeting Nectin-4. Also provided herein are the uses and methods of the antibodies or antigen-binding fragments thereof, or the antibody-drug conjugates in treating cancers.

The present disclosure provides conjugates of anti-Nectin-4 antibodies or antigen binding fragments thereof to a myeloid cell agonist, compositions comprising the conjugates, and methods of treating cancer with the conjugates. The present disclosure also provides for anti-Nectin-4 antibodies or antigen binding fragments thereof and method for using the antibodies or antigen binding fragments thereof in treating cancer.

A universal biological prosthesis of acellular dermal matrix (ADM) intended for use in body reconstruction processes and method of manufacture. A universal biological prosthesis of acellular dermal matrix (ADM) intended for use in body reconstruction processes, comprising: a first layer of ADM of biological origin arranged inferiorly to delimit a cavity with a lower edge; a filling material disposed in the cavity surrounded by the first layer of ADM consisting of a ground ADM having the consistency of a fibrous paste; and a second layer of ADM of biological origin arranged on the upper part covering the filling material and whose upper edge rests peripherally on the lower edge of the first layer of ADM, thus defining a rim;where the first layer of ADM and the second layer of ADM are joined by an eyebrow overlap along the upper edge of the first layer of ADM with the lower edge of the peripheral rim using a biocompatible adhesive, or by absorbable suture; where the first layer of ADM, the second layer of ADM and the ADM filling material are not immunogenic; and where the ADM comprises collagen fibers, fibronectin, elastin, laminin, glycosaminoglycans and hyaluronic acid. Method for its manufacture.

The invention relates to the technical field of artificial dermis, in particular to a preparation method and application of artificial dermis based on bionic acellular matrix. The artificial dermis comprises a bionic acellular matrix component A and an auxiliary material component B, wherein the component A comprises type I collagen, type VI collagen, elastin, fibronectin, laminin, mother cell protein and glucan; the component B comprises antibacterial peptide, antibiotics and a high-molecular polymer material; the mass ratio of the component A to the component B is (4-6): (1-4). The preparation method comprises the following steps: respectively preparing procedure mother liquor of the component A and the component B, preparing hydrogel with a double-layer gradient structure through step-by-step crosslinking, and then carrying out freeze drying and sterilization treatment. The artificial dermis disclosed by the invention has good biocompatibility and antibacterial property, can effectively promote wound healing, is suitable for repairing acute and chronic wounds of four limbs, faces and trunk parts, and is particularly suitable for repairing complex wounds with exposed bones, tendons, nerves and blood vessels.

The invention provides a serum-free medium for maintaining dryness of mesenchymal stem cells as well as a preparation method and application of the serum-free medium, and belongs to the technical field of biological medicines. The serum-free culture medium comprises a basic culture medium and an exogenous additive component, the basic culture medium is a DMEM / F12 culture medium, and the exogenous additive components comprise bFGF, EGF, PDGF-BB, recombinant human fibronectin, laminin, insulin, transferrin, sodium selenate, beta-mercaptoethanol and ascorbic acid. The serum-free culture medium provided by the invention is a special culture medium for the mesenchymal stem cells, which is completely free of animal-derived components, is suitable for large-scale amplification of clinical-grade cell treatment products, is relatively low in preparation cost and high in stem differentiation capability, and can remarkably improve the proliferation efficiency of the cultured mesenchymal stem cells.

Provided herein are peptides and conjugates, including radionuclide conjugates, useful in compositions and methods of treating, diagnosing, monitoring, and / or imaging a disease, disorder, or condition associated with expression of one or more targets, including Nectin-4.

The present application relates to the technical field of artificial dermis, and particularly relates to a preparation method and application of artificial dermis based on biomimetic acellular matrix. The artificial dermis comprises a biomimetic acellular matrix component A and an auxiliary component B, wherein the component A comprises type I collagen, type VI collagen, elastin, fibronectin, laminin, matricellular protein and dextran; the component B comprises antibacterial peptide, antibiotic and high molecular polymer material; the mass ratio of the component A to the component B is (4-6):(1-4). The preparation method comprises the steps of respectively preparing A and B component process mother liquor, step-by-step crosslinking to prepare a hydrogel with a double-layer gradient structure, and then freeze-drying and sterilization treatment. The artificial dermis has good biocompatibility and antibacterial performance, can effectively promote wound healing, and is suitable for repairing acute and chronic wounds of limbs, facial parts and trunk parts, and is particularly suitable for repairing complex wounds with exposed bones, tendons, nerves and blood vessels.

The application provides a multi-specific antibody monomer having a light chain (LC) and a heavy chain (HC), each having a N-terminal and a C-terminal, comprising, a first scFv domain having a binding affinity to a tumor-associated antigen (TAA) at the N-terminal of the HC (Position 1, or P1), a Fab domain having a binding affinity to CD3, and a second scFv domain having a binding affinity to PD-L1 at the C-terminal of the LC (Position 5, or P5) or the N-terminal of the LC (Position 6, or P6). In some embodiments, the TAA comprises EGFR, HER3, DLL3, HER2, GPC3, HLA-G, uPAR, Nectin4, Fra, Tissue Factor, B7-H4, VEGFR2, B7-H3, Muc16, CEACAM6, Claudin6, CLDN18.2, LGR5, GCC, CD20, CD19, Integrin β6, Muc1, CDH6, FAP, CAIX, Integrin β4, CDH17, Lewis B / Y, GPRC5D, CEACAM5, ROR1, or EGFR vIII.

The application discloses application of a separating enzyme inhibitor in preparation of an antitumor drug, and the separating enzyme inhibitor is toxoflavin and a derivative thereof. The compound can inhibit, at a molecular level, cleavage activity of an important proteinase, namely separating enzyme, on one subunit Scc1 of a mucin; at a cellular level, the toxoflavin derivative Walrycin B can inhibit proliferation of cancer cells such as human cervical cancer (HeLa), liver cancer (HepG2), breast cancer (MCF-7) and prostate cancer (PC3), and can arrest the cell cycle of the cancer cells at a G2 / M phase; and at an allogeneic transplantation tumor animal model, the Walrycin B can significantly inhibit growth of a mouse tumor.

The invention is directed to a composition of soluble placental ECM in storage solution and the methods of manufacture related thereto. The solubilized placental ECM solution is manufactured through a process of partitioning placental ECM from the placental tissue in a high acidic pH environment and performing an ultrafiltration step and diafiltration step through a tangential flow filtration system to increase the pH. The soluble placental ECM retains the native characteristics of placental ECM components and includes collagens (types I, III, V, VI, IX, and X), elastin, laminin, and fibronectin.

Disclosed herein are Nectin-4 antibodies. In some embodiments, the Nectin-4 antibodies can be used in treatments such as, for example, cancer treatments.

The invention provides a solution to deficiencies in innate immune cell targeting in solid tumors, including bladder cancer, through IL-18 or IL-15 Tetra protein targeted Killer Engagers (TetraKEs). These leverage CD16 and CD56 to enhance natural killer (NK) cell targeting of Nectin-4+ bladder tumor cells, offering a novel immunotherapeutic approach.

The invention relates to the technical field of biomedical materials, and discloses a freeze-dried matrigel and a preparation method and application thereof, and the freeze-dried matrigel is prepared by dissolving a natural basement membrane extract in a high-glucose DMEM (Dulbecco Modified Eagle Medium); the natural basement membrane extract is derived from EHS mouse tumor tissue rich in extracellular matrix proteins. The freeze-dried matrigel provided by the invention is prepared by taking a natural basement membrane extract as a core active component through an optimized freeze-drying process. After redissolution, a three-dimensional fiber network structure can be quickly recovered, the biological functions of active ingredients such as collagen IV, laminin and nest protein in the basement membrane are reserved, and the storage stability is high; meanwhile, the matrix gel has the advantages of good redissolution effect and good cell compatibility, can be widely applied to the fields of cell culture and in-vitro disease model construction, and solves the technical problems that the traditional liquid matrix gel needs to be stored at low temperature, is high in transportation cost and is easy to degrade and inactivate.

To provide a novel composition for application on the skin of human or the like that prevents the deterioration of skin function.SOLUTION: The present invention provides a composition that comprises tranexamic acid for inhibiting the degradation of laminin 511 in the skin.SELECTED DRAWING: None

The present invention provides antigen-binding proteins capable of binding to Nectin-4 polypeptides conjugated to chemotherapeutic agents, for use in increasing sensitivity of tumors to the chemotherapeutic agents, for use in the treatment of cancers characterized by Nectin expressing tumor cells. In one embodiment, the present invention provides conjugates of an anti-Nectin-4 antibody to a camptothecin analogue, such as exatecan or SN-38, through a cleavable linker.

The present application relates to a kind of laminin or its specific fragment polypeptide, the complex formed by non-covalent adsorption immunological factor with it and its application in biomaterials.38 polypeptides screened by the present application. One or more of the complete laminin containing the polypeptide screened by the present application, or complete fibronectin is used as carrier protein, and is mixed with biomaterial base, immunological factor etc. to make complex, because there is non-covalent adsorption between carrier protein and immunological factor, immunological factor can be biomimetic adsorption carried on the material combined with carrier protein. The product containing the complex of the present application can automatically dissociate and release immunological factor in neutral environment and maintain the slow release for several days.Moreover, the product made of the complex of the present application can avoid activating the immune response of the implant, solve the problem that transgenic expression vector enters the patient's body and easily induces intense immune response, difficult to realize secondary administration etc.

Provided are an anti-Nectin-4 antibody and the use thereof. The anti-Nectin-4 antibody or antigen-binding fragment can specifically bind to Nectin-4 and has high affinity and strong endocytosis capacity, and therefore can be used for diagnosis, prevention, and / or treatment of tumors (comprising cancers and benign tumors).

To find out a new function of Myonectin and to provide a suitable use thereof.SOLUTION: The myonectin production promoter is contained in a composition for inhibiting IL-1 α expression. The composition is preferably in the form of an external preparation for skin or a food or drink.SELECTED DRAWING: Figure 1

Disclosed herein are an anti-Nectin-4 antibody, an antibody-drug conjugate thereof, and use thereof. The anti-Nectin-4 antibody and the antibody-drug conjugate thereof can be used for treating a disease.

A tricyclic polypeptide conjugated drug and the use thereof are provided. Specifically provided are a compound as represented by formula (III), and a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprising a therapeutically or prophylactically effective amount of the compound or the pharmaceutically acceptable salt thereof is further provided. The compound or the pharmaceutically acceptable salt thereof and the pharmaceutical composition can be used in the preparation of a drug for treating Nectin-4 overexpressed solid tumors.

The present invention provides methods for identifying or selecting cancer patients for treatment with a Nectin-4 targeted therapeutic on the basis of the patients having a Nectin-4 copy number of 4 or more.

The objective is to provide therapeutic drugs that promote wound healing. [Solution] Analysis of Dectin-1 gene-deficient mice revealed that inhibiting Dectin-1 promotes wound healing caused by burns. When laminarin, a Dectin-1 antagonist, or barley β-glucan 30sp was administered to the wound, a significant wound healing promoting effect was observed. Since low molecular weight β-glucan, a Dectin-1 antagonist, has the effect of promoting wound healing, a wound healing promoter containing it as an active ingredient can be provided.

The present invention relates to a camelina cake extract and a composition comprising said extract, for a cosmetic treatment. The extract according to the invention has anti-aging, propigmenting and moisturising effects, by acting on the production of various molecules such as hyaluronic acid, collagen, laminins and melanin, and on the inhibition of oxidation, radicals and glycation.

Provided is an antibody molecule that binds to human Nectin-4 or a fragment thereof. The antibody is obtained by means of hybridoma screening and humanization techniques, and is used for the prevention or treatment of a cancer, and may be used as a clinical lead drug molecule.

The inventors developed a multiplex test for the detection of autoantibodies directed against nine DEJ proteins (NC16A, C-terminal and LAD-1 domains of BP180, BP230, α6β4 Integrin, NC1 and NC2 domains of collagen VII and γ1 and β4 chains of P200 laminin).) in patient's sera, in order to establish a specific diagnosis. The multiplex test is based on the use of microbeads coated with recombinant or purified DEJ proteins, which can be analyzed by flow cytometry or Luminex® technology. The multiplex test allows the simultaneous measurement of multiple autoantibodies in a single sample, reducing the cost, time, and volume of serum required. The multiplex test also has the potential to improve the sensitivity and specificity of the diagnosis, as well as to provide prognostic and therapeutic information for the management of patients with autoimmune bullous diseases.

The invention discloses a lentiviral vector and an application of the lentiviral vector in preparation of a medicine for treating bordering epidermis bullosa. Compared with an existing gene therapy technology based on gamma-retrovirus for transmitting hLAMB3, the lentiviral vector has the advantages that the lentiviral vector can be used for treating bordering epidermis bullosa; when being applied and expressed in a skin tissue sheet generated by autologous keratinocytes, the screened beta3 sublaminin-5 protein expression cassette, the lentivirus transfer plasmid, the lentivirus packaging system, the lentivirus vector particles, the genetically engineered cells and the pharmaceutical composition have both safety and high efficiency.

This invention provides a complex protein composition, product, and application for improving skin condition. The complex protein composition includes type IV collagen, type VII collagen, type XVII collagen, laminin 332, and fibronectin. This complex protein composition helps to improve skin condition, delay the appearance of aging, reduce wrinkles, and improve sagging. Simultaneously, it plays a positive role in repairing and supporting the skin barrier and extracellular matrix structure, which is beneficial for maintaining the stability and orderly remodeling of the skin microenvironment.

The present disclosure provides Nectin-4 antibody drug conjugates (ADCs) comprising exatecan and pharmaceutical compositions thereof, and methods of using the ADCs for the treatment of cancer.

The invention relates to a universal biological acellular dermal matrix (ADM) prosthesis for use in body reconstruction processes, comprising: a first layer of ADM of biological origin, arranged at the bottom to delimit a cavity with a bottom edge; a packing material which is arranged in the cavity surrounded by the first ADM layer and consists of ground ADM material having the consistency of a fibrous pulp; and a second layer of ADM of biological origin which is arranged on the upper part and covers the packing material and the top edge of which rests, at its periphery, on the bottom edge of the first layer of ADM, thereby defining a rim; wherein the first layer of ADM and the second layer of ADM are joined by precisely arranging the upper edge of the first layer of ADM on top of the bottom edge of the rim, at the periphery, using a biocompatible glue or using sutures made of resorbable thread; wherein the first layer of ADM, the second layer of ADM and the ADM packing material are not immunogenic; and wherein the ADM comprises collagen fibres, fibronectin, elastin, laminin, glycosaminoglycans and hyaluronic acid. The invention also relates to a method for producing same.